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REVIEW
Finding all BRCA pathogenic mutation carriers: best
practice models
Nicoline Hoogerbrugge* and Marjolijn CJ Jongmans
Identifying germline BRCA pathogenic mutations in patients with ovarian or breast cancer is a crucial component in the medical
management of affected patients. Furthermore, the relatives of affected patients can be offered genetic testing. Relatives who test
positive for a germline BRCA pathogenic mutation can take appropriate action to prevent cancer or have cancer diagnosed as early
as possible for better treatment options. The recent discovery that BRCA pathogenic mutation status can inform treatment decisions
in patients with ovarian cancer has led to an increased demand for BRCA testing, with testing taking place earlier in the patient
care pathway. New approaches to genetic counselling may be required to meet this greater demand for BRCA testing. This review
discusses the need for best practices for genetic counselling and BRCA testing; it examines the challenges facing current practice
and looks at adapted models of genetic counselling.
European Journal of Human Genetics (2016) 24, S19–S26; doi:10.1038/ejhg.2016.95
INTRODUCTION
It is well established that individuals carrying a germline BRCA1 or
BRCA2 pathogenic mutation have an elevated lifetime risk of
developing ovarian cancer (40% and 18% by age of 70 years for
BRCA1 and BRCA2, respectively) or breast cancer (57% and 49% by
age of 70 years for BRCA1 and BRCA2, respectively).1 Prospective
cancer-risk data from the EMBRACE study in the UK show similar
numbers; average cumulative risk of ovarian cancer by age of 70 years
in BRCA1 and BRCA2 pathogenic mutation carriers is 59% and 17%,
respectively; and 60% and 55%, respectively, for breast cancer.2
Although guidelines differ between countries and regions, genetic
testing is used predominantly to determine the BRCA pathogenic
mutation status and assess the cancer risk in patients with a high
probability of an inherited predisposition, which is currently based in
particular on a family history for breast and ovarian cancer or, for
instance, Jewish ancestry.3–6 Pathogenic mutation carriers are offered
regular surveillance and/or prophylactic mastectomies or prophylactic
salpingo-oophorectomies, which have been shown to reduce the risk
of developing cancer.7,8
In view of the elevated lifetime risk of developing ovarian or breast
cancer associated with germline BRCA pathogenic mutations, it is
important that relatives of those patients who developed ovarian or
breast cancer because of a germline BRCA pathogenic mutation are
offered germline BRCA testing. Those relatives who are conﬁrmed as
carrying a germline BRCA pathogenic mutation can then take
appropriate action in order to prevent cancer or have cancer diagnosed
as early as possible for better treatment options.
Recent studies have reported that patients with ovarian cancer
who carry a BRCA pathogenic mutation have longer survival rates,
a favourable response to platinum-based chemotherapy and may
demonstrate sensitivity to novel treatments such as inhibitors of
poly(ADP)-ribose polymerase (PARP), which target the DNA repair
pathway that is defective in the tumour cells of carriers.9–12 By
focussing on family history while selecting patients eligible for BRCA
testing, 15–44% of women with ovarian cancer, who are BRCA
pathogenic mutation carriers but appear to have no family risk factors,
are missed.9,13–16 With the prospect of targeted treatment options
on the horizon and the high prevalence of BRCA pathogenic mutations
among patients with ovarian cancer, there is a case for expanding
genetic testing to all women with ovarian cancer regardless of family
history and to screen not only for germline BRCA pathogenic mutations
in this setting but also for somatic BRCA pathogenic mutations.9,17
BRCA testing guidelines vary considerably between countries, but
there is an evolving trend to look beyond family cancer history. For
instance, the National Comprehensive Cancer Network, the American
Congress of Obstetricians and Gynecologists and the revised Dutch
guidelines recommend BRCA genetic testing for patients with ovarian
cancer, irrespective of family history, and the Scottish Intercollegiate
Guidelines Network guideline 135 recommends offering BRCA genetic
testing to all women with non-mucinous ovarian cancer or fallopian
tube cancer, irrespective of family history; however, other guidelines,
including the European Society for Medical Oncology clinical practice
guidelines and some country-speciﬁc guidelines, rely on family history
of breast cancer and/or ovarian cancer.4–6,18,19
Undeniably, this increase in demand for BRCA testing will have an
impact on the current genetic testing process. Current practice in
many countries requires face-to-face counselling with a qualiﬁed
genetic counsellor or a clinical geneticist both before and after BRCA
testing.3,5 One could argue that there will be a need for more genetic
professionals in order to cope with increasing demands, but new
approaches for delivering genetic counselling can also be explored.
This review gives an overview of alternative procedures for genetic
counselling and testing of patients at risk of hereditary breast and
ovarian cancer, with a focus on patients with ovarian cancer. On the
basis of these examples and the experienced advantages and disadvan-
tages, a novel best practice model for patients with ovarian cancer
is proposed, to ensure that patients and relatives receive consistency
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of care and that sequence variants are interpreted and managed
appropriately.20
The effect of new treatment options on the existing BRCA testing
process
Utilising BRCA testing to inform treatment selection is likely to add
greater complexity to the existing testing process (Figure 1). Early
and rapid BRCA testing has already been introduced in the workﬂow
of many centres for newly diagnosed women with breast cancer who
have characteristics of an inherited predisposition, in order to inform
surgical decisions (eg, bilateral mastectomy).21 Because of the implica-
tions of test results on patients and their families (ie, raised cancer risk),
current practice in many countries requires face-to-face counselling
with a qualiﬁed genetics counsellor both before and following BRCA
testing.22 As genetic testing may take place early in routine patient
care in order to guide management decisions, the content and timing of
genetic counselling is likely to change in the future.23
As models of genetic counselling evolve, a multidisciplinary team of
professionals, including clinical geneticists, gynaecologists, surgeons,
radiotherapists and medical oncologists will be increasingly involved
in the process.23 Any future model of BRCA testing and genetic
counselling will need to address a range of issues that arise in genetic
counselling. For example, broader cancer gene testing may lead to a
higher probability of identifying a ‘variant of unknown signiﬁcance’
rather than a known pathogenic mutation, which requires careful
interpretation and sensitive explanation by a clinical geneticist.24,25 In
addition, clinicians need to be aware of the different clinical con-
sequences of a somatic versus a germline pathogenic BRCA mutation.
Furthermore, if a negative BRCA result is received, other less frequent
genetic causes of cancer predisposition need to be considered.
The effect of genetic testing reaches beyond the patient with cancer
and affects the entire family. Not only are there consequences for
relatives once a pathogenic BRCA mutation is found but also when no
such mutation is found, as the relative may still have a high familial
risk for cancer and the need for cancer prevention. Currently, the
majority of oncologists are not accustomed to calculating and
communicating cancer risks for relatives.26 The information provided
to patients and their relatives needs to be consistent among all
members of the multidisciplinary team and a clinical geneticist must
be part of this team. Importantly, professionals involved in BRCA
testing need to be aware of the psychological consequences of BRCA
genetic testing, which may result in distress during the testing process
and/or after carrier status is identiﬁed.27–29
MODELS OF GERMLINE BRCA TESTING
Research is currently being undertaken on novel approaches to BRCA
testing and genetic counselling.24,30–32 These alternative processes may
act as a guide to optimal practice as the demand for access to genetic
counsellors and clinical geneticists increases. The following section
outlines four approaches to genetic counselling and discusses the
associated issues and beneﬁts of each in the context of current practice.
Current practice: the Huntington protocol
Because of the potentially far-reaching implications of BRCA suscept-
ibility testing, a lighter version of the ‘Huntington protocol’ was
adopted for the counselling of unaffected individuals who wanted
to determine whether they had inherited a familial pathogenic
mutation in BRCA.22 Predictive testing is generally offered solely to
adults at risk, who have had the appropriate counselling, are fully
informed and wish to proceed.22 The guidelines recommend that
individuals who undergo predictive testing are seen for two to four
counselling sessions, spread over a 3-month period, before disclosure
of the test results.22 If a pathogenic mutation is found, counselling
must be offered to the family and others involved.
The pre-test counselling sessions allow for advance consideration of
medical options and the impact that test results may have on the
individual as well as on family members, while post-test counselling
provides a valuable opportunity for health-care providers to interpret
test results and to decide whether additional genetic testing is needed.
For instance, in women with ovarian cancer and a family history for
colorectal cancer, analysis of the mismatch repair genes may reveal
Lynch syndrome. Another item in the post-counselling is to emphasise
the importance of continuing regular preventive activities for the
patient and for relatives if indicated.33 For example, if a patient receives
a negative BRCA test result, a personalised and intensiﬁed breast
surveillance protocol in agreement with increased familial cancer risk
as calculated from the exact family history is often advised for speciﬁc
female relatives. Therefore, relatives may beneﬁt from cancer preven-
tion both in cases of a pathogenic mutation in BRCA or in cases of
a positive family history hinting at a high familial cancer risk.
Potential 
implications 
of new treatments 
on the BRCA 
testing process
Faster turnaround times required
Tests will be undertaken at diagnosis or in the early treatment phase
Results need to be delivered rapidly to inform treatment decisions
More complex tests
Testing for germline and somatic pathogenic 
mutations will generate a more 
complex output in the lab
Increased workload
More patients will require tests for specific 
mutations or full gene screens
Extra implications of 
false-negative results
A robust methodology is required to 
provide accurate outputs because 
false-negative results could affect 
treatment choices and patient outcomes
Cost implications
Costs per test may increase due to 
greater test complexity or decrease due 
to the increase in patients being tested 
Figure 1 New treatment options will have an impact on existing BRCA testing processes.
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Although there are local or national variations of this process, the
universal characteristic is the need for at least one pre-test counselling
session with a genetic counsellor or a clinical geneticist. The strength of
this approach is the face-to-face contact with a health-care professional
who is speciﬁcally trained in discussing the medical and psychological
implications of genetic testing; however, this approach may no longer
be possible in the era of treatment-based genetic counselling, which
demands faster turnaround times.23
The ‘DNA-direct’ model (The Netherlands)
The ‘DNA-direct’ model is a telephone-based genetic counselling
model for patients with breast cancer. It is a novel approach that
replaces the initial consultation with a telephone call (to provide
information, not counselling) and written and digital information,
which is sent home with the patient; face-to-face counselling is offered
only after BRCA testing, where the counsellor discloses the DNA
results and delivers customised advice to the patient (Figure 2).32
The aim of this process is to eliminate extraneous information,
which is not applicable to the individual patient, and to provide
patients with the information they desire in a quick and patient-centric
manner.32
In a study of 161 eligible patients with breast cancer, patients chose
either the DNA-direct approach or a traditional DNA-intake approach.
The DNA-intake approach offered pre-test face-to-face genetic coun-
selling. The patients who chose the DNA-direct approach received
an information package, which included an information letter, a link
to a website and access to a short educational movie about hereditary
breast cancer and DNA-testing. An appointment for a personal
consultation to disclose the results was set for 8 weeks after DNA-
testing commenced.32 The fact that patients were not randomised
between the two methods of counselling enabled the researchers to
measure the percentage of patients that opted for the DNA-direct
approach. This study design however introduced a bias and does not
allow a thorough comparison between the two approaches.
Overall, 59% of patients chose the DNA-direct approach, of whom
89% were satisﬁed and would choose DNA-direct again (including 6/8
carriers of a pathogenic BRCA mutation). The self-reported reasons
for choosing the DNA-direct or the DNA-intake approach can be seen
in Figure 3.32
Patient characteristics differed signiﬁcantly between the approaches
(Figure 3). Participants who had previously received information
about personal consequences of hereditary breast cancer, or used
websites for breast cancer information, were more likely to choose
DNA-direct.32 Those who had received information about genetics in
general or who experienced higher decisional conﬂict were more likely
to choose DNA-intake.
General distress and heredity-speciﬁc distress scored lower in the
DNA-direct group than the DNA-intake group both at baseline and at
follow-up 2 weeks after BRCA result disclosure.32 Quality of life, breast
cancer worry, risk perception for hereditary breast cancer and second
breast cancer did not differ between DNA-direct versus DNA-intake
or over time. BRCA pathogenic mutation detection rate was equal
between procedures at 8%. Processing time (triage call to patient
BRCA result disclosure) was reduced by 1 month with the DNA-direct
(70 days) versus the DNA-intake (103 days; P= 0.002) approach.32
The total duration of face-to-face contact time was diminished from
60 to 30 min (unpublished data). It is worth noting that processing
times are health-system dependent and may vary elsewhere.32
The authors concluded that before BRCA testing, more patients
with breast cancer preferred replacing a face-to-face consultation with
a trained genetic counsellor by a home information package including
telephone, written and digital information. The majority of patients
were strongly to moderately satisﬁed with the procedure without
increased distress compared with the face-to-face intake approach.32
Beneﬁts attributed to the DNA-direct approach included the ability
to review information at home without having to attend additional
hospital/clinic appointments and perceived faster turnaround times;
however, this approach may not be suited to all patients. The authors
suggest that it may be most appropriate for patients who match the
overall proﬁle of DNA-direct participants – more highly educated and
better informed patients, who are more certain of genetic testing and
show less distress.32
Telephone-based counselling model (USA)
The telephone-based counselling model was made for healthy relatives
or patients after successful breast or ovarian cancer treatment. Genetic
counselling offered via telephone has the potential to broaden the reach
and accessibility of BRCA1/BRCA2 testing – especially in rural areas or
where there is limited access to genetic counselling resources – and to
reduce costs (Figure 4).31
A study by Schwartz et al.31 compared telephone delivery of BRCA
genetic counselling with in-person delivery. Women aged 21–85 years,
who did not have newly diagnosed or metastatic cancer and who lived
within a study site catchment area, were randomly assigned to usual care
or telephone counselling. Usual care participants received in-person
pre- and post-test counselling while telephone counselling participants
completed all counselling by telephone. Telephone counselling was
non-inferior to usual care on all primary outcomes (Figure 5).
One area where telephone counselling was not equivalent to usual
care was on BRCA test uptake: 84% of patients randomised to
telephone counselling went on to have a BRCA test compared with
90% following usual care. Patients receiving usual care could supply a
DNA sample directly after their counselling session, whereas telephone-
counselled patients had to travel to a clinic to provide a sample.
Moreover, the time between the telephone counselling session and
Post-BRCA testing 
face-to-face consultation 
based on test result
BRCA testing
Pre-BRCA testing: patient 
receives telephonic, written 
and digital information
Figure 2 The DNA-direct approach for patients with breast cancer to genetic counselling.
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attending the clinic may have provided time for deliberation and
reconsideration, leading patients to forgo testing.
The outcome of this study might have been inﬂuenced by the fact
that ‘direct-to-consumer’ genetic testing is offered by numerous
companies in the USA and therefore is more common practice than
in other countries. Especially in Europe, this is not common practice.
In our opinion, it is important to note that telephone counselling
may not be appropriate for newly diagnosed patients with cancer or
patients with metastatic cancer, for whom the reassurance of face-to-
face guidance is important.
Royal Marsden testing model (UK)
At the Royal Marsden Hospital in London a new mainstreaming
model for BRCA testing in patients with ovarian cancer has been
implemented.34 This pathway requires non-geneticists to undertake
online training and follow clear protocols that delineate the patient
pathway and the approval process (Figure 6).
This approach aims to bring gene testing to the patient through
their existing oncology appointments. Trained members of the
oncology team manage the pre-test consultation; however, patients
are referred to the Cancer Genetics Unit if more detailed discussions
are required. Any patient found to carry a pathogenic mutation is seen
by a geneticist in the Cancer Genetics Unit; those with normal results
are referred to the Cancer Genetics Unit only if requested by the
patient.
In a pilot from July to December 2013, 119 women with either non-
mucinous ovarian cancer diagnosed ato65 years or ovarian or breast
cancer at any age were tested.34 No patients requested additional
Cancer Genetics Unit input before the test. Among the 119 women
tested, 20 patients (17%) carried a pathogenic mutation (BRCA1 n= 8,
BRCA2 n= 12). Of those with a pathogenic mutation, 60% were
assessed as having no family history of breast and/or ovarian cancer.
Nine of the carriers of a pathogenic mutation had an immediate
change in management due to BRCA status. It should be noted that
data on family history from this study were not validated or checked
and no data are available on uptake of BRCA cascade testing in
relatives.
SOMATIC (TUMOUR) PATHOGENIC MUTATIONS IN BRCA: IS
THERE A CASE FOR TESTING PRIOR TO GERMLINE TESTING?
Although research has demonstrated that germline pathogenic muta-
tions in BRCA1/BRCA2 in ovarian cancer can deregulate homologous
recombination (HR), and thereby increase a patient’s sensitivity to
platinum-based chemotherapy and possibly to treatment with PARP
Patients with breast cancer referred 
for genetic counselling (n=161)
Chose DNA-intake n=66/161 (41%) Chose DNA-direct n=95/161 (59%)
Reasons for choosing:
     • Personal contact
     • Asking questions
     • Bringing family
Reasons for choosing:
     • Faster results
     • Practical reasons e.g. no travel time/ 
       extra hospital visits
     • Sufficient information
Patient characteristics:   
     • Lower educational level
     • Higher decisional conflict
     • Prior information about genetics in 
       general from the referring physician
Patient characteristics:
     • More highly educated
     • Better informed
     • More certain of genetic testing
     • Website use for breast cancer 
       information or prior information about 
       personal consequences of hereditary 
       breast cancer
Figure 3 Patient characteristics and their reasons for choosing DNA-intake or DNA-direct approaches.
Post-BRCA testing tele-
phone counselling 
consultation
BRCA testing
Pre-BRCA testing: patient 
receives telephone 
counselling
Figure 4 The telephone-based counselling model for healthy relatives or patients after successful breast cancer treatment.
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For healthy relatives or patients after successful breast or ovarian cancer treatment, 
women 21–85 years ≥10% BRCA risk, not newly diagnosed or with metastatic disease (N=669)
90% of usual care patients underwent testing vs 84% of those randomised to telephone counselling
Telephone counselling was non-inferior to in-person counselling (at 2 weeks and 3 months) for:
  • Post-counselling knowledge score (assessed only at 2 weeks)
  • Decisional conflict 
  • Cancer distress
  • Perceived stress 
  • Satisfaction with counselling (assessed only at 2 weeks)
  • Physical/mental functioning (assessed only at 3 months)
Follow-up interviews conducted 2 weeks post- 
counselling (pre-test disclosure), and at 3, 6 and 
12 months after assignment (post-test disclosure)
Allocated to telephone pre- and post-test 
counselling (n=335)
Allocated to usual care, pre- and post-test
in-person counselling (n=334)
Randomisation
Figure 5 Telephone counselling was non-inferior to usual care on all primary outcomes.
Patient with:
• non-mucinous ovarian cancer diagnosed 
  at <65 years
• ovarian or breast cancer at any age
Cancer Genetics Unit issue results. Report and 
notification to clinician by EPR within 8 weeks
BRCA pathogenic 
mutation
No BRCA pathogenic
mutation
• Clinician gives result to patient
• Genetics appointment letter  
  sent 3 weeks after report 
  issued to Oncology
ACTIONS by approved clinician
1.  Information sheet (MS IS1) given to patient
2.  BRCA testing discussed
3.  Consent obtained and scanned onto electronic patient 
     record (EPR)
4.  Blood sample and request form sent to lab
5.  EPR notification to Cancer Genetics Unit
Refer to Cancer 
Genetics Unit
More 
discussion 
required
• Clinician gives result and
  information sheet (MS IS2) 
  to patient
• Genetics appointment offered
  on request
Figure 6 The Royal Marsden BRCA testing model.31
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inhibitors, few studies have investigated the potential impact of
somatic sequence variants on BRCA function.9–12
A recently published study has demonstrated that germline and
somatic pathogenic mutations in HR genes (BRCA1, BRCA2, ATM,
BARD1, BRIP1, CHEK1, CHEK2, FAM175A, MRE11A, NBN, PALB2,
RAD51C and RAD51D) occur in ~ 31% of patients with serous or
non-serous ovarian cancer.12 Of these, 75% of germline HR mutations
and 71% of somatic HR mutations were in BRCA.12 Patients with
a germline or somatic HR pathogenic mutation were more sensitive
to primary platinum chemotherapy and experienced improved overall
survival (66 months, germline HR mutation; 59 months, somatic HR
mutation; and 41 months, no HR mutation) compared with patients
with no HR pathogenic mutations.12
The role of somatic pathogenic BRCA mutations in platinum-based
chemotherapy sensitivity, and their potential role in PARP inhibitor
sensitivity, suggests that the number of women with ovarian cancer
who might beneﬁt from these treatments is greater than predicted
by the frequency of germline pathogenic mutations.10 Consequently,
there is a possible case for the inclusion of somatic pathogenic
mutation testing in the BRCA testing process.
The ‘Nijmegen tumour analysis plan’ is one such proposed genetic
counselling pathway that includes BRCA testing of ovarian tumour
samples from newly diagnosed patients with ovarian cancer as a means
of pre-screening for germline BRCA testing. The beneﬁt of this plan
is twofold. First, this allows more effective recognition of patients
who may beneﬁt from PARP inhibitor treatments. Second, and equally
important, these patients are also eligible for germline BRCA-analysis
to determine hereditary cancer risks in their relatives, who may beneﬁt
from cancer-prevention measures. Half of the tumour BRCA patho-
genic mutations are accompanied by a germline BRCA pathogenic
mutation.35 Therefore, the use of tumour BRCA testing as a pre-screen
for germline BRCA testing would reduce the number of patients
referred for genetic counselling and increase the pathogenic mutation
detection rate of germline BRCA testing from 12 to 50%. We are aware
that tumour BRCA testing poses several challenges for laboratories,
which are discussed in the accompanying article by Andrew Wallace
(New challenges for BRCA testing: a view from the diagnostic laboratory).
SUMMARY OF BRCA TESTING AND COUNSELLING MODELS
It is possible that future BRCA testing and counselling models will
incorporate different elements of those models described above. In
Figure 7, a hypothetical BRCA testing model is described for a broader
ovarian cancer population that keeps the patient and their relatives well
informed of the test consequences throughout the process. In this
model, all newly diagnosed patients with epithelial ovarian cancer receive
an initial BRCA test of tumour samples guided by a gynaecologist. For
those patients testing positive for a BRCA tumour pathogenic mutation
with or without a positive family history of cancer, a clinical geneticist
would provide counselling before germline BRCA testing. On the basis
of patient preferences, this could be via telephone with additional
educational resources provided in the form of written and digital
information. Following germline BRCA testing, all patients would be
provided with face-to-face genetic counselling with a clinical geneticist.
Patients who test negative for a BRCA tumour pathogenic mutation but
have a positive family history of cancer would also be referred for genetic
counselling.
There is still some ambiguity amongst national and society guidelines
on the universal approach of BRCA testing for all newly diagnosed
patients with ovarian cancer, with several still having a requirement
of a pre-test probability threshold to be met before genetic testing is
offered.36 Arguments for having a pre-test probability threshold are
generally based on the cost implications and potential overload to
Guidance by oncologist
(medic/gynaecologist) 
Germline BRCA
pathogenic 
mutation analysis
Clinical geneticist
 counselling
Negative test and 
no family history:
STOP
Positive test:
Clinical geneticist
counselling
Ovarian tumour 
BRCA pathogenic 
mutation analysis
All patients with 
epithelial ovarian cancer
Test results to 
inform treatment
Including digital 
information and/or 
telephone counselling
Negative test and positive 
family history of cancer 
e.g. colorectal cancer
Figure 7 Summary BRCA testing and counselling model for a broad ovarian cancer population.
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existing health-care infrastructure and services.36 There will also be
some patients who will not choose to have genetic testing performed
due to ethical/religious beliefs or comorbidities such as psychological
conditions.
THE IMPORTANCE OF EDUCATION AND THE MANAGEMENT
OF PATIENT PREFERENCES IN THE GENETIC COUNSELLING
PROCESS
Educating women and their families on the consequences of genetic
testing so that they can make an informed decision about whether
to proceed is a central tenet of the genetic counselling process. In
most women, this can be achieved successfully through face-to-face
or telephone-based consultations with clinical geneticists, or at home
via printed and digital media.24,30–32
Patients at risk of a hereditary predisposition are likely to prefer
information that is speciﬁc to their familial risk of cancer and the
treatment or prophylactic options available to them over general
information on genetics.37 Providing personalised information as early
as possible and reducing the long period of uncertainty during the
genetic diagnostic process may prove helpful.32
Studies have consistently reported high levels of inaccurate risk
perception in women at high risk, even after counselling.38 Therefore,
health-care professionals involved in the genetic counselling process
must be adequately trained to ensure that genetic test results are
correctly interpreted and the potential consequences of those results
are clearly and consistently communicated to the patient.
A single approach to genetic counselling may not be appropriate for all
patients. Although the majority of patients are comfortable with receiving
pre-test information via telephone, print or digital media, others express
a preference for the personal contact of a face-to-face consultation with a
clinical geneticist.32,39 Determining patient preferences early in the
genetic counselling process, and ensuring that the process is ﬂexible
enough to accommodate a range of preferences, will ensure that both the
needs of the patient and of her relatives are adequately met.23
CONCLUSIONS
In many countries, genetic counselling before BRCA testing is carried
out face-to-face by a qualiﬁed genetic counsellor or a clinical geneticist.
Germline BRCA testing without prior face-to-face genetic counselling
could be considered for selected patients who are adequately informed
by their oncologist together with telephone, digital or written informa-
tion from a clinical geneticist. This could include all patients with
ovarian cancer and breast cancer patients with a positive family history
of breast or ovarian cancer.
There is a general consensus that after a positive BRCA test result
or in cases of highly suggestive family history for hereditary cancer,
face-to-face counselling with a clinical geneticist is important in
order to discuss the consequences of the results for the patient and
other family members, as well as to explain complex test results and
other hereditary causes of cancer. Evidence suggests that there is a case
for extending genetic testing to all patients with ovarian cancer; the
inclusion of genetic testing for somatic pathogenic mutations may also
prove valuable. In the era of personalised care and treatment-based
genetic counselling these approaches may form the basis of optimising
future workﬂow.
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